Astrazeneca annual shareholders’ equity
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Shareholders’ Equity Growth & History (AZN)
Astrazeneca's shareholders’ equity was $48.67B for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $48.67B | $7.88B | +19.32% |
| 2024 | 2024-12-31 | $40.79B | $1.64B | +4.20% |
| 2023 | 2023-12-31 | $39.14B | $2.11B | +5.69% |
| 2022 | 2022-12-31 | $37.04B | −$2.23B | −5.68% |
| 2021 | 2021-12-31 | $39.27B | $23.65B | +151.36% |
| 2020 | 2020-12-31 | $15.62B | $2.50B | +19.01% |
| 2019 | 2019-12-31 | $13.13B | $659.0M | +5.29% |
| 2018 | 2018-12-31 | $12.47B | −$2.49B | −16.66% |
| 2017 | 2017-12-31 | $14.96B | $106.0M | +0.71% |
| 2016 | 2016-12-31 | $14.85B | −$3.64B | −19.66% |
| 2015 | 2015-12-31 | $18.49B | — | — |
Astrazeneca quarterly shareholders’ equity
Q4.17
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $50.30B | $5.58B | +12.47% |
| Q1 2026 | 2026-03-31 | $47.33B | — | — |
| Q4 2025 | 2025-12-31 | $48.67B | $7.88B | +19.32% |
| Q3 2025 | 2025-09-30 | $45.89B | — | — |
| Q2 2025 | 2025-06-30 | $44.72B | $5.21B | +13.18% |
| Q4 2024 | 2024-12-31 | $40.79B | $1.64B | +4.20% |
| Q2 2024 | 2024-06-30 | $39.51B | $2.12B | +5.67% |
| Q4 2023 | 2023-12-31 | $39.14B | $2.11B | +5.69% |
| Q2 2023 | 2023-06-30 | $37.39B | $1.46B | +4.06% |
| Q4 2022 | 2022-12-31 | $37.04B | −$2.23B | −5.68% |
| Q2 2022 | 2022-06-30 | $35.93B | $20.26B | +129.22% |
| Q4 2021 | 2021-12-31 | $39.27B | $23.65B | +151.36% |
| Q2 2021 | 2021-06-30 | $15.68B | $3.44B | +28.10% |
| Q4 2020 | 2020-12-31 | $15.62B | $2.50B | +19.01% |
| Q2 2020 | 2020-06-30 | $12.24B | −$1.31B | −9.68% |
| Q4 2019 | 2019-12-31 | $13.13B | $659.0M | +5.29% |
| Q2 2019 | 2019-06-30 | $13.55B | $903.0M | +7.14% |
| Q4 2018 | 2018-12-31 | $12.47B | −$2.49B | −16.66% |
| Q2 2018 | 2018-06-30 | $12.64B | — | — |
| Q4 2017 | 2017-12-31 | $14.96B | — | — |
Astrazeneca shareholders’ equity trends
Over the last five fiscal years, Astrazeneca's shareholders’ equity increased from $15.62B to $48.67B, a change of $33.05B. The latest reported quarter, Q2 2026, shows $50.30B.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...